Literature DB >> 2900131

Systemic and regional haemodynamic profile of diuretics and alpha- and beta-blockers. A review comparing acute and chronic effects.

A Mimran1, G Ducailar.   

Abstract

The influence of the acute and chronic administration of antihypertensive agents on blood flow to various organs which are known targets of hypertension is important in the determination of drug therapy for this disorder. In association with the frequently observed fall in cardiac output and increase in total peripheral resistance in response to acute administration, beta-blockers may induce a decrease in blood flow to the brain and kidney. However, during chronic treatment it has been widely shown that total peripheral resistance returns to pretreatment levels (except for labetalol, a beta-blocker with alpha-blocking properties) whilst renal and cerebral blood flows are unaffected. Although alpha-blockers acutely lower blood pressure and induce a baroreflex-mediated increase in heart rate and cardiac output while not affecting cerebral blood flow, during chronic treatment no change in systemic or cerebral or renal blood flow is observed. Diuretics and dietary sodium restriction, which are the most widely used therapeutic interventions, are usually well tolerated; however, in aged patients in whom renal adaptation to sodium depletion is impaired, deterioration of renal function may be observed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2900131     DOI: 10.2165/00003495-198800356-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  56 in total

1.  The effect of acebutolol on the cerebral circulation of man.

Authors:  P Hares; I M James; D Griffith
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

2.  The effect of beta-adrenergic receptor blocking drugs on cerebral blood flow.

Authors:  D N Griffith; I M James; P A Newbury; M L Woollard
Journal:  Br J Clin Pharmacol       Date:  1979-05       Impact factor: 4.335

3.  Comparison of the acute hemodynamic effects of intravenous celiprolol and propranolol in patients with suspected coronary disease.

Authors:  G Gensini; C Dator; P Esente; F S Caruso; T Solomon
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

4.  The renin response to diuretic therapyl A limitation of antihypertensive potential.

Authors:  E D Vaughan; R M Carey; M J Peach; J A Ackerly; C R Ayers
Journal:  Circ Res       Date:  1978-03       Impact factor: 17.367

5.  Renal function during long-term treatment of hypertension with minoxidil: comparison of benign and malignant hypertension.

Authors:  H C Mitchell; R M Graham; W A Pettinger
Journal:  Ann Intern Med       Date:  1980-11       Impact factor: 25.391

6.  beta-Adrenoceptor-blocking agents and the kidney: effect of nadolol and propranolol on the renal circulation.

Authors:  N K Hollenberg; D F Adams; D N McKinstry; G H Williams; L J Borucki; J M Sullivan
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

7.  Recovery of renal function in patients with accelerated malignant nephrosclerosis on maintenance dialysis with management of blood pressure by captopril.

Authors:  G Mourad; A Mimran; C M Mion
Journal:  Nephron       Date:  1985       Impact factor: 2.847

8.  Short- and long-term (six-year) hemodynamic effects of labetalol in essential hypertension.

Authors:  P Lund-Johansen
Journal:  Am J Med       Date:  1983-10-17       Impact factor: 4.965

9.  Contrasting renal haemodynamic responses to the angiotensin converting enzyme inhibitor enalapril and the beta-adrenergic antagonist metoprolol in essential hypertension.

Authors:  D T O'Connor; C A Mosley; J Cervenka; K N Bernstein
Journal:  J Hypertens Suppl       Date:  1984-12

10.  Renal filtration fraction, effective vascular compliance, and partition of fluid volumes in sustained essential hypertension.

Authors:  G M London; M E Safar; J A Levenson; A C Simon; M A Temmar
Journal:  Kidney Int       Date:  1981-07       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.